These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 12820361

  • 1. Tumor M2-PK levels in haematological malignancies.
    Oremek GM, Rox S, Mitrou P, Sapoutzis N, Sauer-Eppel H.
    Anticancer Res; 2003; 23(2A):1135-8. PubMed ID: 12820361
    [Abstract] [Full Text] [Related]

  • 2. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
    Wechsel HW, Petri E, Bichler KH, Feil G.
    Anticancer Res; 1999; 19(4A):2583-90. PubMed ID: 10470199
    [Abstract] [Full Text] [Related]

  • 3. [Tissue factor (TF) and inhibitor (TFPI) concentrations in patients with urinary tract tumors and haematological malignancies].
    Radziwon P, Schenk JF, Mazgajska K, Boczkowska-Radziwon B, Galar M, Kłoczko J, Wojtukiewicz MZ.
    Pol Merkur Lekarski; 2002 Oct; 13(76):308-11. PubMed ID: 12557438
    [Abstract] [Full Text] [Related]

  • 4. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma.
    Oremek GM, Teigelkamp S, Kramer W, Eigenbrodt E, Usadel KH.
    Anticancer Res; 1999 Oct; 19(4A):2599-601. PubMed ID: 10470201
    [Abstract] [Full Text] [Related]

  • 5. Pre-analytical problems in the measurement of tumor type pyruvate kinase (tumor M2-PK).
    Oremek GM, Gerstmeier F, Sauer-Eppel H, Sapoutzis N, Wechsel HW.
    Anticancer Res; 2003 Oct; 23(2A):1127-30. PubMed ID: 12820359
    [Abstract] [Full Text] [Related]

  • 6. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy.
    Nisman B, Yutkin V, Nechushtan H, Gofrit ON, Peretz T, Gronowitz S, Pode D.
    Urology; 2010 Aug; 76(2):513.e1-6. PubMed ID: 20573390
    [Abstract] [Full Text] [Related]

  • 7. Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma.
    Oremek GM, Sapoutzis N, Kramer W, Bickeböller R, Jonas D.
    Anticancer Res; 2000 Aug; 20(6D):5095-8. PubMed ID: 11326675
    [Abstract] [Full Text] [Related]

  • 8. Value of tumor M2-PK in thyroid carcinoma: a pilot study.
    Bena-Boupda NF, Rezai SS, Klett R, Eigenbrodt E, Bauer R.
    Anticancer Res; 2003 Aug; 23(6D):5237-40. PubMed ID: 14981996
    [Abstract] [Full Text] [Related]

  • 9. Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies.
    Hock BD, McKenzie JL, Patton NW, Drayson M, Taylor K, Wakeman C, Kantarjian H, Giles F, Albitar M.
    Cancer; 2006 May 15; 106(10):2148-57. PubMed ID: 16598754
    [Abstract] [Full Text] [Related]

  • 10. Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases.
    Schneider J, Morr H, Velcovsky HG, Weisse G, Eigenbrodt E.
    Cancer Detect Prev; 2000 May 15; 24(6):531-5. PubMed ID: 11198266
    [Abstract] [Full Text] [Related]

  • 11. Value of the serum levels of the tumor marker TUM2-PK in pancreatic cancer.
    Oremek GM, Eigenbrodt E, Rädle J, Zeuzem S, Seiffert UB.
    Anticancer Res; 1997 May 15; 17(4B):3031-3. PubMed ID: 9329593
    [Abstract] [Full Text] [Related]

  • 12. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures.
    Elia S, Massoud R, Guggino G, Cristino B, Cortese C, De Massimi AR, Zenobi R.
    Eur J Cardiothorac Surg; 2008 Apr 15; 33(4):723-7. PubMed ID: 18261916
    [Abstract] [Full Text] [Related]

  • 13. Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study.
    Bianco E, Marcucci F, Mele A, Musto P, Cotichini R, Sanpaolo MG, Iannitto E, De Renzo A, Martino B, Specchia G, Montanaro M, Barbui AM, Nieddu R, Pagano L, Rapicetta M, Franceschi S, Mandelli F, Pulsoni A, Italian Multi-Center case-control study.
    Haematologica; 2004 Jan 15; 89(1):70-6. PubMed ID: 14754608
    [Abstract] [Full Text] [Related]

  • 14. Pyruvate kinase type tumor M2 plasma levels in patients afflicted with rheumatic diseases.
    Oremek GM, Müller R, Sapoutzis N, Wigand R.
    Anticancer Res; 2003 Jan 15; 23(2A):1131-4. PubMed ID: 12820360
    [Abstract] [Full Text] [Related]

  • 15. Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor.
    Negaard HF, Iversen PO, Østenstad B, Iversen N, Holme PA, Sandset PM.
    Thromb Haemost; 2008 Jun 15; 99(6):1040-8. PubMed ID: 18521506
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The pyruvate kinase isoenzyme M2 (Tu M2-PK) as a tumour marker for renal cell carcinoma.
    Weinberger R, Appel B, Stein A, Metz Y, Neheman A, Barak M.
    Eur J Cancer Care (Engl); 2007 Jul 15; 16(4):333-7. PubMed ID: 17587357
    [Abstract] [Full Text] [Related]

  • 18. Diagnostic and prognostic value of plasma tumor M2 pyruvate kinase in periampullary cancer: evidence for a novel biological marker of adverse prognosis.
    Goonetilleke KS, Mason JM, Siriwardana P, King NK, France MW, Siriwardena AK.
    Pancreas; 2007 Apr 15; 34(3):318-24. PubMed ID: 17414054
    [Abstract] [Full Text] [Related]

  • 19. Biannual report of the Cochrane Haematological Malignancies Group.
    Trelle S, Higgins G, Kober T, Engert A.
    J Natl Cancer Inst; 2004 Aug 04; 96(15):E2. PubMed ID: 15292394
    [No Abstract] [Full Text] [Related]

  • 20. Copper levels in patients with hematological malignancies.
    Kaiafa GD, Saouli Z, Diamantidis MD, Kontoninas Z, Voulgaridou V, Raptaki M, Arampatzi S, Chatzidimitriou M, Perifanis V.
    Eur J Intern Med; 2012 Dec 04; 23(8):738-41. PubMed ID: 22920946
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.